[2002]-[BNP7787]-[Future Oncology Issues a Comprehensive Report on Clinical and Market Developments in the Taxane Group of Spindle Poisons]
All in all, this issue of FUTURE ONCOLOGY covers:
agents used in combination with taxanes to fight MDR and/or mitigate the drugs' side effects including AVI-4557, BNP7787, cyclosporin A and analogs/derivatives, GF120918, ONT-093, Prosaptide, R101933, tRA96023, VX-710, and XR9576
companies that are sources of taxane raw materials and/or are developing/marketing generic paclitaxel such as Abbott Laboratories, Aphios, Biolyse Pharma, Dabur India, eXegenics, Faulding, Indena, IVAX, Mylan Laboratories, NaPro BioTherapeutics, Natural Pharmaceuticals, Phytogen Life Sciences, Phyton, Samyang Genex and Xechem International
novel formulations and agents including ABI-007, BAY 59-8862 (IDN5109), BMS-184476, BMS-188797, BMS-275183, DJ-927, fibrinogen-coated emulsion formulation of docetaxel, Genetaxyl, LEP (PNU-93914), OncoGel, Paclimer Microspheres, PacoExtra, Paxoral, PEG-paclitaxel, PG-TXL (CT-2103), RPR109881, RPR116258A, S-8184, Taxoprexin, Taxosomes, tumor-activated prodrug (TAP)-taxane immunoconjugates, TL-139, TXD258 (TAX 258), among others
oncologyknowledgebase.com |
